Amyris Inc. AMRS recently announced the completion of the earlier announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance Squalane, Neossance Hemisqualane and CleanScreen.
The terms of the agreement include a $200 million up-front cash payment, a performance-based earnout of up to $150 million and a long-term manufacturing contract. This values the entire transaction at roughly $500 million.
Amyris and Givaudan have collaborated to leverage the former’s technological platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients. This marketing alliance builds on the development and commercialization of the world's largest supply of Bisabolol from Amyris' precision fermentation platform.
This transaction represents the continuation of Amyris' successful execution of its strategy to develop, scale and manufacture the world's best-performing molecules from clean, sustainable chemistry, as well as to partner with the world's leading companies. The company owns the technology and, through its portfolio of best-in-category consumer brands, creates and delivers the best-performing consumer products, driving market demand and adoption of its ingredients.
Shares of Amyris have lost 69.9% over the past year compared with 6.6% decline of its industry.
Image Source: Zacks Investment Research
On its fourth-quarter earnings call, the company stated that total revenues are expected to increase 95-100% year over year for 2023. AMRS anticipates that the transaction with Givaudan will generate $200 million in license revenues in the second quarter of 2023. The company also forecasts that its consumer brands will continue outperforming the industry in skin care, hair care, color cosmetics, baby care and healthy aging. Amyris estimates a $55 million capital expenditure for 2023, a 50% reduction from 2022.
Amyris, Inc. Price and Consensus
Amyris, Inc. price-consensus-chart | Amyris, Inc. Quote
Zacks Rank & Key Picks
AMRS currently carries Zacks Rank #3 (Hold).
Better-ranked stocks worth considering in the basic materials space include Steel Dynamics, Inc. STLD, Reliance Steel & Aluminum RS, and Olympic Steel, Inc. ZEUS.
Steel Dynamics currently carries a Zacks Rank #1 (Strong Buy). Shares of STLD have gained 23.7% in the past year. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 11.32% on average. You can see the complete list of today’s Zacks #1 Rank stocks here.
Reliance Steel currently carries a Zacks Rank #1. Shares of RS have gained 32.1% in the past year. Reliance topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 13.4% on average.
Olympic Steel currently carries a Zacks Rank #1. Shares of ZEUS have gained 30.3% in the past year. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 26.2% on average.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Steel Dynamics, Inc. (STLD) : Free Stock Analysis Report
Reliance Steel & Aluminum Co. (RS) : Free Stock Analysis Report
Amyris, Inc. (AMRS) : Free Stock Analysis Report
Olympic Steel, Inc. (ZEUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
"ingredients" - Google News
April 10, 2023 at 05:26PM
https://ift.tt/wV0BRY7
Amyris (AMRS) and Givaudan Close Cosmetic Ingredients Deal - Yahoo Finance
"ingredients" - Google News
https://ift.tt/iR6USZW
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "Amyris (AMRS) and Givaudan Close Cosmetic Ingredients Deal - Yahoo Finance"
Post a Comment